Phase 2b Trial Opens for Rodatristat Ethyl, Potential PAH-modifying Therapy

Phase 2b Trial Opens for Rodatristat Ethyl, Potential PAH-modifying Therapy

293798

Phase 2b Trial Opens for Rodatristat Ethyl, Potential PAH-modifying Therapy

Altavant Sciences has opened ELEVATE 2, its global Phase 2b clinical trial into the safety and efficacy of rodatristat ethyl, a potential disease-modifying oral therapy for people with pulmonary arterial hypertension (PAH). The proof-of-concept study (NCT04712669) is expected to enroll about 90 adults with diagnosed, symptomatic WHO Group 1 PAH, which includes idiopathic (unknown cause), heritable, and toxin-induced disease. Contact information is available here, and the company expects sites to span the U.S., Canada, and Europe.   In…

You must be logged in to read/download the full post.